190 related articles for article (PubMed ID: 36257538)
1. Epigenetics in advanced renal cell carcinoma: Potential new targets.
Molina-Cerrillo J; Santoni M; Ruiz Á; Massari F; Pozas J; Ortego I; Gómez V; Grande E; Alonso-Gordoa T
Crit Rev Oncol Hematol; 2022 Dec; 180():103857. PubMed ID: 36257538
[TBL] [Abstract][Full Text] [Related]
2. Current Status and Future Directions of Immunotherapy in Renal Cell Carcinoma.
Considine B; Hurwitz ME
Curr Oncol Rep; 2019 Mar; 21(4):34. PubMed ID: 30848378
[TBL] [Abstract][Full Text] [Related]
3. Targeting Tyrosine kinases in Renal Cell Carcinoma: "New Bullets against Old Guys".
Alonso-Gordoa T; García-Bermejo ML; Grande E; Garrido P; Carrato A; Molina-Cerrillo J
Int J Mol Sci; 2019 Apr; 20(8):. PubMed ID: 30999623
[TBL] [Abstract][Full Text] [Related]
4. Checkpoint Inhibitors for the Treatment of Renal Cell Carcinoma.
Ghatalia P; Zibelman M; Geynisman DM; Plimack ER
Curr Treat Options Oncol; 2017 Jan; 18(1):7. PubMed ID: 28210995
[TBL] [Abstract][Full Text] [Related]
5. Epigenetics in renal cell cancer: mechanisms and clinical applications.
Joosten SC; Smits KM; Aarts MJ; Melotte V; Koch A; Tjan-Heijnen VC; van Engeland M
Nat Rev Urol; 2018 Jul; 15(7):430-451. PubMed ID: 29867106
[TBL] [Abstract][Full Text] [Related]
6. Next Wave of Targets in the Treatment of Advanced Renal Cell Carcinoma.
Cardenas LM; Deluce JE; Khan S; Gulam O; Maleki Vareki S; Fernandes R; Lalani AA
Curr Oncol; 2022 Jul; 29(8):5426-5441. PubMed ID: 36005167
[TBL] [Abstract][Full Text] [Related]
7. PD-1 blockade therapy in renal cell carcinoma: current studies and future promises.
Massari F; Santoni M; Ciccarese C; Santini D; Alfieri S; Martignoni G; Brunelli M; Piva F; Berardi R; Montironi R; Porta C; Cascinu S; Tortora G
Cancer Treat Rev; 2015 Feb; 41(2):114-21. PubMed ID: 25586601
[TBL] [Abstract][Full Text] [Related]
8. MicroRNAs Associated with Von Hippel-Lindau Pathway in Renal Cell Carcinoma: A Comprehensive Review.
Schanza LM; Seles M; Stotz M; Fosselteder J; Hutterer GC; Pichler M; Stiegelbauer V
Int J Mol Sci; 2017 Nov; 18(11):. PubMed ID: 29165391
[TBL] [Abstract][Full Text] [Related]
9. Facts and Hopes for Immunotherapy in Renal Cell Carcinoma.
Yao C; Zhang T; Wu T; Brugarolas J
Clin Cancer Res; 2022 Dec; 28(23):5013-5020. PubMed ID: 35819272
[TBL] [Abstract][Full Text] [Related]
10. Genetics and epigenetics of renal cell cancer.
Baldewijns MM; van Vlodrop IJ; Schouten LJ; Soetekouw PM; de Bruïne AP; van Engeland M
Biochim Biophys Acta; 2008 Apr; 1785(2):133-55. PubMed ID: 18187049
[TBL] [Abstract][Full Text] [Related]
11. Integrated Molecular Characterization of Fumarate Hydratase-deficient Renal Cell Carcinoma.
Sun G; Zhang X; Liang J; Pan X; Zhu S; Liu Z; Armstrong CM; Chen J; Lin W; Liao B; Lin T; Huang R; Zhang M; Zheng L; Yin X; Nie L; Shen P; Zhao J; Zhang H; Dai J; Shen Y; Li Z; Liu J; Chen J; Liu J; Wang Z; Zhu X; Ni Y; Qin D; Yang L; Chen Y; Wei Q; Li X; Zhou Q; Huang H; Yao J; Chen N; Zeng H
Clin Cancer Res; 2021 Mar; 27(6):1734-1743. PubMed ID: 33414138
[TBL] [Abstract][Full Text] [Related]
12. New anti-angiogenic targeted therapy in advanced renal cell carcinoma (RCC): current status and future prospects.
Sciarra A; Gentile V; Salciccia S; Alfarone A; Di Silverio F
Rev Recent Clin Trials; 2008 May; 3(2):97-103. PubMed ID: 18474019
[TBL] [Abstract][Full Text] [Related]
13. Check point inhibitors a new era in renal cell carcinoma treatment.
Alsharedi M; Katz H
Med Oncol; 2018 May; 35(6):85. PubMed ID: 29728867
[TBL] [Abstract][Full Text] [Related]
14. Synergistic effects of the immune checkpoint inhibitor CTLA-4 combined with the growth inhibitor lycorine in a mouse model of renal cell carcinoma.
Li X; Xu P; Wang C; Xu N; Xu A; Xu Y; Sadahira T; Araki M; Wada K; Matsuura E; Watanabe M; Zheng J; Sun P; Huang P; Nasu Y; Liu C
Oncotarget; 2017 Mar; 8(13):21177-21186. PubMed ID: 28416753
[TBL] [Abstract][Full Text] [Related]
15. Gut Bacteria Composition Drives Primary Resistance to Cancer Immunotherapy in Renal Cell Carcinoma Patients.
Derosa L; Routy B; Fidelle M; Iebba V; Alla L; Pasolli E; Segata N; Desnoyer A; Pietrantonio F; Ferrere G; Fahrner JE; Le Chatellier E; Pons N; Galleron N; Roume H; Duong CPM; Mondragón L; Iribarren K; Bonvalet M; Terrisse S; Rauber C; Goubet AG; Daillère R; Lemaitre F; Reni A; Casu B; Alou MT; Alves Costa Silva C; Raoult D; Fizazi K; Escudier B; Kroemer G; Albiges L; Zitvogel L
Eur Urol; 2020 Aug; 78(2):195-206. PubMed ID: 32376136
[TBL] [Abstract][Full Text] [Related]
16. Genetic and epigenetic alterations during renal carcinogenesis.
Arai E; Kanai Y
Int J Clin Exp Pathol; 2010 Dec; 4(1):58-73. PubMed ID: 21228928
[TBL] [Abstract][Full Text] [Related]
17. Immune checkpoint inhibitors in advanced renal cell carcinoma: experience to date and future directions.
Atkins MB; Clark JI; Quinn DI
Ann Oncol; 2017 Jul; 28(7):1484-1494. PubMed ID: 28383639
[TBL] [Abstract][Full Text] [Related]
18. Epigenetic inactivation of HOXA11, a novel functional tumor suppressor for renal cell carcinoma, is associated with RCC TNM classification.
Wang L; Cui Y; Sheng J; Yang Y; Kuang G; Fan Y; Jin J; Zhang Q
Oncotarget; 2017 Mar; 8(13):21861-21870. PubMed ID: 28423531
[TBL] [Abstract][Full Text] [Related]
19. Update on immunotherapy for renal cancer.
Canales Rojas R
Medwave; 2021 Jun; 21(5):e8202. PubMed ID: 34214067
[TBL] [Abstract][Full Text] [Related]
20. Molecular pathways in renal cell carcinoma: recent advances in genetics and molecular biology.
Su D; Singer EA; Srinivasan R
Curr Opin Oncol; 2015 May; 27(3):217-23. PubMed ID: 25811348
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]